Journal Publications
4
2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19
2024
Sam Schulman, Donald M Arnold, Charlotte A Bradbury, Lisa Broxmeyer, Jean Marie Connors, Anna Falanga, Toshiaki Iba, Scott Kaatz, Jerrold H Levy, Saskia Middeldorp, Tracy Minichiello, Ishac Nazy, Eduardo Ramacciotti, Helaine E Resnick, Charles Marc Samama, Michelle Sholzberg, Jecko Thachil, Ryan Zarychanski, Alex C Spyropoulos, International Society on Thrombosis
5
Illustrated State-of-the-Art Capsules of the ISTH 2024 Congress
2024
Chris Ward, Nicola Curry, Magdy El-Ekiaby, Kerstin Jurk, Henri H Versteeg, Charithani Keragala, Tal Burstyn-Cohen, Silvio Antoniak, Yuko Suzuki, Ross I Baker, Olivier Christophe, Shoshana Revel-Vilk, Alice Hart, Carsten Deppermann, Huyen Tran, Nicola Pozzi, Walter HA Kahr, Steven P Grover, Philip Wenzel, Ashley C Brown, Cécile Oury, Susan M Shea, James Fredenburgh, Freda H Passam, James Winearls, Hunter B Moore, Soumitra Tole, Eileen Merriman, Geoffrey D Barnes, Z Leonardo Liu, Michelle Sholzberg
6
Human Fc gamma receptor IIIA blockade inhibits platelet destruction in a humanized murine model of ITP
2024
Lazaro Gil Gonzalez, Kevin D Won, Zoya Tawhidi, Emma Cummins, Yoelys Cruz-Leal, Yaima Tundidor Cabado, Ulrich J Sachs, Peter AA Norris, Yuexin Shan, Varsha Bhakta, Janessa Li, Ismael Samudio, Begonia Silva-Moreno, Liza Cerna-Portillo, Alequis Pavon Oro, Peter Bergqvist, Patrick Chan, Amy Moorehead, Michelle Sholzberg, William P Sheffield, Alan H Lazarus
7
Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi
2024
Elliot B Tapper, Matthew A Warner, Rajesh P Shah, Juliet Emamaullee, Nancy M Dunbar, Michelle Sholzberg, Jacqueline N Poston, Robin J Soto, Ammar Sarwar, Anjana Pillai, Karina Reyner, Shivang Mehta, Marwan Ghabril, Timothy R Morgan, Stephen Caldwell
8
Randomized controlled trials of switching to a new medication vs continuing a chronic medication may underestimate the risk of adverse events in those continuing because of asymmetric depletion of susceptibles
2024
Michael Colacci, Afsaneh Raissi, Prachi Ray, Michelle Sholzberg, Kenneth J Rothman, Michael Fralick
9
Thrombopoietin receptor agonists and other second-line therapies for Immune Thrombocytopenia: a narrative review with a focus on Drug Access in Canada
2024
Joanne Britto, Anne Holbrook, Haowei Sun, Christine Cserti-Gazdewich, Oksana Prokopchuk-Gauk, Cyrus Hsia, Karima Khamisa, Paul R Yenson, Michelle Sholzberg, Harold J Olney, Sudeep Shivakumar, David Jones, Hayley Merkeley, Jacqueline Costello, Erin Jamula, Donald M Arnold
11
Overview of the Safety Profile From Efgartigimod Clinical Trials in Participants With Diverse IgG-Mediated Autoimmune Diseases
2024
Michelle Sholzberg, Kelly Gwathmey, Catherine M Broome, Matthias Goebeler, Hiroyuki Murai, Zsuzsanna Bata-Csörgo, Adrian Newland, Peter Ulrichts, Rene Kerstens, Jeffrey T Guptill, Sofiane Agha, Ming Jiang, James F Howard Jr
2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19
Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi
Human Fc gamma receptor IIIA blockade inhibits platelet destruction in a humanized murine model of ITP
Randomized controlled trials of switching to a new medication vs continuing a chronic medication may underestimate the risk of adverse events in those continuing because of asymmetric depletion of susceptibles
Tranexamic acid for management of heavy vaginal bleeding: barriers to access and myths surrounding its use
Increased risk of haematological malignancy in adults over age 60 with thrombocytopenia compared with matched controls: Time for an upfront bone marrow evaluation?
Thrombopoietin receptor agonists and other second-line therapies for Immune Thrombocytopenia: a narrative review with a focus on Drug Access in Canada
Overview of the Safety Profile From Efgartigimod Clinical Trials in Participants With Diverse IgG-Mediated Autoimmune Diseases
Pre-Operative Coagulation Test Results Do Not Correlate with Self-Bleeding Assessment Tool (Self-BAT) Scores
Facilitators and Barriers to Accessing Antifibrinolytic and Iron Therapies for Patients Who Menstruate-a Global Healthcare Provider Survey
Initial Report of Part B Phase 1/2 Efficacy and Safety Results for Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed Immune Thrombocytopenia
Evaluating Hemoglobin Thresholds on the Basis of Sex: Preliminary Insights from a Systematic Review
High Prevalence of Subjective Minimizing Language in Clinical Trials of Hematologic Malignancies: Natural Language Processing (NLP) Validation Study and Systematic Review of Randomized Controlled Trials Presented at ASH 2009-2021
An Approach to Hemequity: Identifying the Barriers and Enablers of Iron Deficiency Reduction Strategies in Low-to-Middle-Income Countries
Evaluating Sex-Based Hemoglobin Reference Intervals Using Strict Definitions of Health
Iron Surveillance and Management in Gastro-Intestinal Oncology Patients: A National Physician Survey
Evaluation of the association of factor XIII at hospital arrival and outcomes in a cohort of severely injured patients
Safety Profile of Efgartigimod from Clinical Trials in Participants with Immunoglobulin G-Mediated Autoimmune Diseases
A Multicentre Cohort Study Evaluating Pregnancy Loss in Patients with Von Willebrand Disease and Unspecified Bleeding Disorders
Obstetrical Decision-Making in Moderate or Severe Hemophilia A and B: A Qualitative Study Exploring Parents' Experiences, Preferences and Needs
Evaluation of the Association of Factor XIII at Hospital Arrival and Outcomes in a Cohort of Severely Injured Patients
Delphi Consensus Recommendations for Neuraxial Anesthesia in Adults with Platelet Disorders and Coagulation Defects
Factor XIII 24-Hour Trajectory Analysis in Severely Injured Patients: Post-hoc Analysis of the Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Study
“Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets”: Reply
Gastrointestinal bleeding in von Willebrand patients: special diagnostic and management considerations
Identification of women and girls with iron deficiency in the reproductive years
Read article
Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets
Prevalence of iron deficiency and iron-deficiency anemia in US females aged 12-21 years, 2003-2020
Defining ferritin clinical decision limits to improve diagnosis and treatment of iron deficiency: A modified Delphi study
Antithrombotic treatment in patients with hemophilia: an EHA-ISTH-EAHAD-ESO clinical practice guidance
A pilot feasibility trial of daily versus every other day oral iron supplementation in patients with iron deficiency anaemia.
Association between diabetes and mortality among adult patients hospitalized with COVID-19: A cohort study of hospitalized adults in ontario, canada, and copenhagen, denmark
Vaginal Blood Loss: A patient-and medical trainee-centered mixed-methods research program
PERI-OPERATIVE ORTHOPEDIC MANAGEMENT OF A PATIENT WITH SEVERE HEMOPHILIA A AND A FACTOR VIII INHIBITOR ON EMICIZUMAB
THE ORIGIN OF FERRITIN REFERENCE INTERVALS: A SYSTEMATIC REVIEW
THE FREQUENCY AND SIGNIFICANCE OF CROSSREACTING ANTI-PORCINE FVIII INHIBITORS IN PATIENTS WITH CONGENITAL AND ACQUIRED HEMOPHILIA A
A CASE OF LYMPHOMA-ASSOCIATED ACQUIRED VON WILLEBRAND SYNDROME RESPONSIVE TO SPLENECTOMY
Proceedings of the immune thrombocytopenia summit: new concepts in mechanisms, diagnosis, and management
Perioperative continuous infusions of factor VIII versus factor IX for patients with hemophilia A or B undergoing major surgery
Address
Li Ka Shing Knowledge Institute
209 Victoria St
Toronto, ON
M5B 1T8